China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AMLPUBT·2 days ago, 08:49 PM09969+2.73%688428+4.32%
InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in ChinaGlobeNewswire·2 days ago, 08:49 PM09969+2.73%688428+4.32%
InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in ChinaGlobeNewswire·Aug 3 at 09:48 PM09969+2.73%688428+4.32%
InnoCare’s Oral Psoriasis Drug ICP‑488 Hits Phase III Target, Paving Path to Regulatory FilingTip Ranks·Jul 27 at 04:37 AM09969+2.73%688428+4.32%
InnoCare says Phase II vitiligo trial of TYK2 inhibitor soficitinib meets primary endpoint at Week 24PUBT·Jul 16 at 03:51 AM09969+2.73%688428+4.32%
InnoCare’s TYK2 Inhibitor Soficitinib Hits Phase III Goal in Atopic DermatitisTip Ranks·Jul 15 at 06:07 AM688428+4.32%09969+2.73%
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLLUnusual Whales·Jul 14 at 06:25 AM09969+2.73%688428+4.32%
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in ChinaGlobeNewswire·Jul 5 at 08:00 PM09969+2.73%688428+4.32%
